catheters chronically implanted in the mesenteric, portal and hepatic veins and in the hepatic artery, and with electromagnetic blood flow probes in the portal vein and hepatic artery, allowing continuous measurement of IGF-I hepatic production. According to a latin square design, these calves received iv mesenteric infusion of calcium (Ca2+; 5 mg/kg) or synthetic salmon calcitonin (sCT; 1 \g=m\g/kg), or synthetic bovine parathyroid hormone (1-34) (bPTH; 1 \g=m\g/kg), or solvent alone (1.2 ml/kg). Ca2+, sCT or bPTH had no significant effect on portal vein or hepatic artery blood flow. Hypercalcemia observed following Ca2+ infusion did not significantly modify hepatic IGF-I production. sCT decreased plasma Ca2+, inorganic phosphorus and GH concentrations and hepatic IGF-I production. bPTH induced a slight hypercalcemia and hypophosphatemia. It had no significant effect on plasma GH concentration, but increased significantly hepatic IGF-I production. Thus, the anabolic effects of PTH on bone may be partly mediated through an increase in hepatic IGF-I production.
Insulin-like growth factor, also called somatomedin C, is a major regulator of bone growth (1) . Many tissues synthesize IGF-I, but the liver appears to be the major site of production (2) . Studies of isolated perfused livers (3), liver expiants in culture (4) , and cultured hepatocytes (5) indicate that hepatic re¬ lease of IGF-I reflects the nutritional and hor¬ monal status.
Parathyroid hormone was recently shown to stimulate the synthesis of IGF-I in osteoblast-enriched (6) and in bone (7) (12) . In rats, plasma IGF-I activity strongly increases during liver regeneration after partial he¬ patectomy (13) (14) . Thus (1) . Thus, IGF-I appears to be an autocrine/paracrine regulator of bone for¬ mation. However, the IGF-I concentrations mea¬ sured in blood plasma imply that it may function as a systemic hormone (31) . Stimulation of hepatic IGF-I synthesis by physiological doses of PTH (Fig.  2) may partly explain the anabolic effects of PTH on bone (9) . Such an effect would not be dependent on changes in plasma Ca2+ induced by PTH since iv Ca2+ infusion does not modify hepatic IGF-I production. Neither does it preclude that PTH may also increase the number of osteoblastic cells (32) .
In conclusion, results obtained by another group (7) , together with those reported here, demon¬ strate that PTH-induced bone anabolism may be mediated by both autocrine/paracrine and endo¬ crine effects of IGF-I on this tissue.
